HLS TherapeuticsTSX:HLS -1.12%62 EBITDA Margin % is 31.42% as of Mar. 2026, which is 10% below its 10-year median of 35.09. GuruFocus rates TSX:HLS with a GF Score™ of 62/100 and a GF Value™ of C$4.46 (Fairly Valued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, HLS Therapeutics ranks better than 87.02% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. HLS Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was C$5.55 Mil. HLS Therapeutics's Revenue for the
three
months ended in Mar. 2026 was C$17.65 Mil. Therefore, HLS Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was 31.42%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HLS Therapeutics EBITDA Margin % Related Terms
HLS Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for HLS Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HLS Therapeutics EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HLS Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLS Therapeutics (TSX:HLS) has a EBITDA Margin % of 31.42% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HLS Therapeutics and its competitors. This is 10% below median its historical median of 35.09. Over the past decade, HLS Therapeutics' EBITDA Margin % has ranged from 20.43 to 72.51. According to the industry distribution chart, HLS Therapeutics ranks #124 out of 955 companies in the Drug Manufacturers industry, placing it in the top 13%.
Is HLS Therapeutics' EBITDA Margin % too high?
HLS Therapeutics' current EBITDA Margin % of 31.42% is 10% below median its 10-year median of 35.09. Over the past 10 years, this metric has ranged from a low of 20.43 to a high of 72.51. The Drug Manufacturers industry median EBITDA Margin % is 12.39. HLS Therapeutics' value of 31.42% is 153.6% above this industry median. Based on the distribution chart, HLS Therapeutics ranks #124 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, HLS Therapeutics has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #124 out of 955 companies for EBITDA Margin %. This places HLS Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.39. HLS Therapeutics' value of 31.42% is 153.6% above this benchmark. Historically, HLS Therapeutics' own EBITDA Margin % has ranged from 20.43 to 72.51 over the past decade. While the company's 10-year median is 35.09 vs. the industry median of 12.39, HLS Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HLS Therapeutics's current EBITDA Margin % of 31.42% is 153.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HLS Therapeutics and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HLS Therapeutics's current EBITDA Margin % is 31.42%, which is 10% below median its own 10-year median of 35.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.46, compared to a current price of C$4.42 — trading 0.9% below its estimated fair value. The current EBITDA Margin % is 31.42%, which is 10% below median its 10-year median of 35.09 and 153.6% above the Drug Manufacturers industry median of 12.39. HLS Therapeutics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current EBITDA Margin % is 31.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of C$4.42 is trading 0.9% below its estimated GF Value™ of C$4.46.
GuruFocus considers HLS Therapeutics to be Fairly Valued.
Key valuation signals for TSX:HLS:
EBITDA Margin %: 31.42% (10% below median its 10-year median of 35.09)
GF Value™: C$4.46 vs. price of C$4.42 (0.9% below fair value)
Industry Position: 153.6% above the Drug Manufacturers median (#124 of 955)
No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
62GF Score
Get the complete analysis for TSX:HLS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:HLS has been successfully added to your 
